Standout Papers

Risdiplam in Type 1 Spinal Muscular Atrophy 2021 2026 2022 2024248
  1. Risdiplam in Type 1 Spinal Muscular Atrophy (2021)
    Giovanni Baranello, Basil T. Darras et al. New England Journal of Medicine
  2. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls (2021)
    Basil T. Darras, Riccardo Masson et al. New England Journal of Medicine

Immediate Impact

3 from Science/Nature 56 standout
Sub-graph 1 of 21

Citing Papers

Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
2025 Standout
Sulfenylnitrene-mediated nitrogen-atom insertion for late-stage skeletal editing of N -heterocycles
2025 StandoutScience
2 intermediate papers

Works of R. Scalco being referenced

Risdiplam, the First Approved Small Molecule Splicing Modifier Drug as a Blueprint for Future Transformative Medicines
2021
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls
2021 Standout

Author Peers

Author Last Decade Papers Cites
R. Scalco 509 475 108 395 61 1.1k
Carmen Morales 271 172 76 268 67 1.3k
Raphaël Rappaport 371 118 136 187 32 1.3k
Meilan M. Rutter 494 155 44 185 49 941
Maria Gueorguiev 291 123 46 353 32 1.4k
Takeshi Shono 386 174 56 348 58 1.2k
Rainer Rossi 465 196 32 155 41 1.2k
Edyta Paczkowska 553 332 35 178 81 1.2k
I. Pénisson-Besnier 682 157 108 131 54 1.1k
Noelyn Hung 448 113 54 154 70 1.2k
Toshiki Doi 417 167 29 197 58 1.2k

All Works

Loading papers...

Rankless by CCL
2026